RBC Capital analyst Ben Hendrix raised the firm’s price target on HCA Healthcare (HCA) to $482 from $449 and keeps an Outperform rating on the shares. The firm was “pleased” to see HCA shares advance after a solid Q3 beat and raise on Friday, with the stronger full year outlook reflecting better than expected core performance, as well as incremental earnings from state supplemental programs, the analyst tells investors in a research note. The management also appears to be voicing greater confidence in its ability to achieve volume growth next year in line with long-term targets, the firm added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCA:
- HCA Healthcare: Hold Rating Amid Policy Uncertainties and Volume Growth Concerns
- HCA Healthcare price target raised to $470 from $430 at BofA
- HCA Healthcare price target raised to $490 from $380 at TD Cowen
- HCA Healthcare price target raised to $494 from $445 at Barclays
- HCA Healthcare price target raised to $525 from $495 at UBS